These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 20046686)

  • 1. Effects of an intravitreal bevacizumab injection combined with panretinal photocoagulation on high-risk proliferative diabetic retinopathy.
    Shin YW; Lee YJ; Lee BR; Cho HY
    Korean J Ophthalmol; 2009 Dec; 23(4):266-72. PubMed ID: 20046686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal bevacizumab (Avastin) and panretinal photocoagulation in the treatment of high-risk proliferative diabetic retinopathy.
    Yang CS; Hung KC; Huang YM; Hsu WM
    J Ocul Pharmacol Ther; 2013; 29(6):550-5. PubMed ID: 23495932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study).
    Tonello M; Costa RA; Almeida FP; Barbosa JC; Scott IU; Jorge R
    Acta Ophthalmol; 2008 Jun; 86(4):385-9. PubMed ID: 17995982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Panretinal photocoagulation versus panretinal photocoagulation plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy.
    Zhou AY; Zhou CJ; Yao J; Quan YL; Ren BC; Wang JM
    Int J Ophthalmol; 2016; 9(12):1772-1778. PubMed ID: 28003978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relation between bevacizumab injection and the formation of subretinal fibrosis in diabetic patients with panretinal photocoagulation.
    Batman C; Ozdamar Y
    Ophthalmic Surg Lasers Imaging; 2010; 41(2):190-5. PubMed ID: 20307036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial.
    Mirshahi A; Roohipoor R; Lashay A; Mohammadi SF; Abdoallahi A; Faghihi H
    Eur J Ophthalmol; 2008; 18(2):263-9. PubMed ID: 18320520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up.
    Arevalo JF; Wu L; Sanchez JG; Maia M; Saravia MJ; Fernandez CF; Evans T
    Eye (Lond); 2009 Jan; 23(1):117-23. PubMed ID: 17891058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study).
    Figueira J; Fletcher E; Massin P; Silva R; Bandello F; Midena E; Varano M; Sivaprasad S; Eleftheriadis H; Menon G; Amaro M; Ayello Scheer S; Creuzot-Garcher C; Nascimento J; Alves D; Nunes S; Lobo C; Cunha-Vaz J;
    Ophthalmology; 2018 May; 125(5):691-700. PubMed ID: 29395119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeated intravitreal bevacizumab (Avastin(®)) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation.
    Schmidinger G; Maar N; Bolz M; Scholda C; Schmidt-Erfurth U
    Acta Ophthalmol; 2011 Feb; 89(1):76-81. PubMed ID: 21272288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contrast sensitivity evaluation in high risk proliferative diabetic retinopathy treated with panretinal photocoagulation associated or not with intravitreal bevacizumab injections: a randomised clinical trial.
    Preti RC; Ramirez LM; Monteiro ML; Carra MK; Pelayes DE; Takahashi WY
    Br J Ophthalmol; 2013 Jul; 97(7):885-9. PubMed ID: 23686001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy.
    Filho JA; Messias A; Almeida FP; Ribeiro JA; Costa RA; Scott IU; Jorge R
    Acta Ophthalmol; 2011 Nov; 89(7):e567-72. PubMed ID: 21726427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-VEGF Therapy for Persistent Neovascularization after Complete Panretinal Photocoagulation in Proliferative Diabetic Retinopathy.
    Mehanna CJ; Abdul Fattah M; Haddad S; Tamim H; Ghazi N; Salti H
    Ophthalmol Retina; 2019 Jun; 3(6):473-477. PubMed ID: 31174668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CHOROIDAL THICKNESS CHANGES IN PROLIFERATIVE DIABETIC RETINOPATHY TREATED WITH PANRETINAL PHOTOCOAGULATION VERSUS PANRETINAL PHOTOCOAGULATION WITH INTRAVITREAL BEVACIZUMAB.
    Roohipoor R; Sharifian E; Ghassemi F; Riazi-Esfahani M; Karkhaneh R; Fard MA; Zarei M; Modjtahedi BS; Moghimi S
    Retina; 2016 Oct; 36(10):1997-2005. PubMed ID: 27046456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.
    Avery RL; Pearlman J; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ; Wendel R; Patel A
    Ophthalmology; 2006 Oct; 113(10):1695.e1-15. PubMed ID: 17011951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal ranibizumab alone or in combination with panretinal photocoagulation for the treatment of proliferative diabetic retinopathy with coexistent macular edema: long-term outcomes of a prospective study.
    Chatziralli I; Dimitriou E; Theodossiadis G; Kazantzis D; Theodossiadis P
    Acta Diabetol; 2020 Oct; 57(10):1219-1225. PubMed ID: 32472172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal bevacizumab for proliferative diabetic retinopathy with new dense vitreous hemorrhage after full panretinal photocoagulation.
    Sinawat S; Rattanapakorn T; Sanguansak T; Yospaiboon Y; Sinawat S
    Eye (Lond); 2013 Dec; 27(12):1391-6. PubMed ID: 24037235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema.
    Soheilian M; Ramezani A; Bijanzadeh B; Yaseri M; Ahmadieh H; Dehghan MH; Azarmina M; Moradian S; Tabatabaei H; Peyman GA
    Retina; 2007; 27(9):1187-95. PubMed ID: 18046223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy.
    Minnella AM; Savastano CM; Ziccardi L; Scupola A; Falsini B; Balestrazzi E
    Acta Ophthalmol; 2008 Sep; 86(6):683-7. PubMed ID: 17995986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of Eyes Lost to Follow-up with Proliferative Diabetic Retinopathy That Received Panretinal Photocoagulation versus Intravitreal Anti-Vascular Endothelial Growth Factor.
    Obeid A; Su D; Patel SN; Uhr JH; Borkar D; Gao X; Fineman MS; Regillo CD; Maguire JI; Garg SJ; Hsu J
    Ophthalmology; 2019 Mar; 126(3):407-413. PubMed ID: 30077614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal bevacizumab (Avastin) prevention of panretinal photocoagulation-induced complications in patients with severe proliferative diabetic retinopathy.
    Mason JO; Yunker JJ; Vail R; McGwin G
    Retina; 2008 Oct; 28(9):1319-24. PubMed ID: 18667958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.